Olmesta M 5/20mg 10Pcs

Indications

This supplement is a well-balanced multivitamin and multimineral supplement that has been clinically calibrated and developed to act as a complete nutritional program for seniors. This preparation helps senior people retain a healthy body and active lifestyle while also ensuring sufficient nourishment.

Pharmacology

Amlodipine is a dihydropyridine calcium channel blocker that inhibits the flow of calcium ions in vascular smooth muscle and myocardium across the membrane. The effect of amlodipine on vascular smooth muscle cells is greater than on cardiomyocytes. Amlodipine is a peripheral arterial vasodilator, which acts directly on vascular smooth muscle, causing a decrease in peripheral vascular resistance and blood pressure.

Angiotensin II is formed by angiotensin I in a reaction catalyzed by an angiotensin-converting enzyme (ACE). It is an effective vasoconstrictor and the main vasoactive hormone of the renin-angiotensin system. High blood pressure is also an important part of pathophysiology. It also stimulates the adrenal cortex to secrete aldosterone.

Olmesartan medoxomil blocks the vasoconstriction and aldosterone secretion of angiotensin II by selectively blocking the binding of angiotensin II to AT1 receptors found in many tissues (such as vascular smooth muscle, and adrenal glands). In vitro binding studies have shown that olmesartan medoxomil is a competitive and reversible AT1 receptor inhibitor. Olmesartan medoxomil does not inhibit ACE (kinase II, an enzyme that converts angiotensin I to angiotensin II and breaks down bradykinin).

Dosage & Administration

Substitute individually titrated components for patients on Amlodipine and Olmesartan Medoxomil. This combination may also be given with increased amounts of Amlodipine, Olmesartan Medoxomil, or both, as needed.

Initial therapy: Initiate with 5/20 mg once daily for 1 to 2 weeks and titrate as needed up to a maximum of 10/40 mg once daily. Due to decreased clearance of Amlodipine among elderly patients, the recommended starting dose of Amlodipine is 2.5 mg in patients 75 years. The lowest dose of the combination is 5/20 mg; therefore, initial therapy with this combination drug is not recommended in patients >75 years old.

Interaction

NSAIDs such as selective COX-2 inhibitors may reduce the antihypertensive impact of angiotensin II receptor antagonists like Olmesartan Medoxomil. In patients receiving combination treatment or other medications that influence the RAS, blood pressure, renal function, and electrolytes should be continuously monitored.

Contraindications

Cannot be co-administered with Aliskiren in patients with diabetes.

Side Effects

Peripheral edema, headache, flushing, and dizziness are the most prevalent adverse effects. It can also cause sprue-like enteropathy, which is a type of intestinal issue.

Pregnancy & Lactation

D is the pregnancy category. The combination of amlodipine and olmesartan medoxomil should not be used in the second or third trimester since it can cause fetal mortality. This combination should be stopped as soon as possible if pregnancy is detected. Olmesartan and Amlodipine are not known to be excreted in human milk. Because of the risk of harm to the nursing infant, a decision should be taken on whether to stop breastfeeding or stop taking the medicine, taking into account the drug's importance to the mother.

Precautions & Warnings

Because of the potential of hypotension in volume- or salt-depleted individuals, the combination of Amlodipine and Olmesartan Medoxomil should be used with caution.

Patients with severe aortic stenosis benefit from vasodilation.

Angina or acute Ml with a higher frequency, length, or severity in patients with significant obstructive coronary artery disease.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.